Sarah Arron, PhD, MD

Dermatologic surgeon

Dr. Sarah Arron, a dermatologic surgeon, is director of the High Risk Skin Cancer Program, which cares for patients who are at risk for skin cancer due to organ transplant, leukemia, lymphoma or genetic syndromes. She specializes in an advanced procedure called Mohs micrographic surgery to treat certain types of skin cancer. Arron also is an expert in facial reconstruction following surgery, laser surgery, dermatology for organ transplant recipients and for those with genetic risk factors for skin cancer. In addition, she performs cosmetic procedures including Botox and soft tissue fillers.

Arron's research interests include studying skin cancer, particularly in patients who are immunosuppressed. She earned a medical degree at Weill Medical College of Cornell University and a doctorate at The Rockefeller University. She completed a residency in dermatology and a fellowship in Mohs micrographic surgery and procedural dermatology at UCSF. Arron is an associate professor in residence of dermatology at UCSF and the Helen Diller Family Comprehensive Cancer Center.

Clinics

Dermatologic Surgery and Laser Center
1701 Divisadero St.
San Francisco, CA 94115
Phone: (415) 353–7878
Fax: (415) 353–7838

Hours: Monday to Friday, 8 a.m. – 5 p.m.

High Risk Skin Cancer Clinic
1701 Divisadero St., Third Floor
San Francisco, CA 94143-0316
Phone: (415) 353-7878
Fax: (415) 353-9503

Hours: Friday by appointment

Melanoma Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-9900
Fax: (415) 885-3802

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Dermatology, American Board of Dermatology

Academic Title

Associate Professor

More about Sarah Arron

Education

Cornell University School of Medicine 2003

Residencies

UCSF Medical Center, Dermatology 2008

Fellowships

UCSF Medical Center, Procedural Dermatology 2007

Selected Research and Publications

  1. Xu MJ, Lazar AA, Garsa AA, Arron ST, Ryan WR, El-Sayed IH, George JR, Algazi AP, Heaton CM, Ha PK, Yom SS. Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. Head Neck. 2018 Mar 10.
  2. Yuan JT, Tello TL, Hultman C, Barker CA, Arron ST, Yom SS. Medical marijuana for the treatment of vismodegib-related muscle spasm. JAAD Case Rep. 2017 Sep; 3(5):438-440.
  3. Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, Chren MM, Arron ST. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017 Oct; 77(4):713-718.
  4. Charruyer A, Fong S, Vitcov GG, Sklar S, Tabernik L, Taneja M, Caputo M, Soeung C, Yue L, Uchida Y, Arron ST, Horton KM, Foster RD, Sano S, North JP, Ghadially R. Brief Report: Interleukin-17A-Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation. Stem Cells. 2017 Aug; 35(8):2001-2007.
  5. Ahn RS, Taravati K, Lai K, Lee KM, Nititham J, Gupta R, Chang DS, Arron ST, Rosenblum M, Liao W. Transcriptional landscape of epithelial and immune cell populations revealed through FACS-seq of healthy human skin. Sci Rep. 2017 May 02; 7(1):1343.
  6. Wei L, Allain DC, Bernhardt MN, Gillespie JL, Peters SB, Iwenofu OH, Nelson HH, Arron ST, Toland AE. Variants at the OCA2/HERC2 locus affect time to first cutaneous squamous cell carcinoma in solid organ transplant recipients collected using two different study designs. Br J Dermatol. 2017 Apr 29.
  7. Yanik EL, Pfeiffer RM, Freedman DM, Weinstock MA, Cahoon EK, Arron ST, Chaloux M, Connolly MK, Nagarajan P, Engels EA. Spectrum of Immune-Related Conditions Associated with Risk of Keratinocyte Cancers among Elderly Adults in the United States. Cancer Epidemiol Biomarkers Prev. 2017 Jul; 26(7):998-1007.
  8. Hibler BP, Saylor DK, Chin-Hong P, Arron ST. Antimicrobial Prophylaxis for Full-Face Laser Resurfacing in Transplant Recipients. Dermatol Surg. 2017 Apr; 43(4):599-604.
  9. Stuart SE, Schoen P, Jin C, Parvataneni R, Arron S, Linos E, Boscardin WJ, Chren MM. Tumor recurrence of keratinocyte carcinomas judged appropriate for Mohs micrographic surgery using Appropriate Use Criteria. J Am Acad Dermatol. 2017 Jun; 76(6):1131-1138.e1.
  10. Yuan JT, Chang TW, Yu SS, Arron ST. Mental Artery Occlusion From Poly-L-Lactic Acid Injection at the Lateral Chin. Dermatol Surg. 2017 Mar 14.
  11. Dizon MP, Linos E, Arron ST, Hills NK, Chren MM. Comparing the Quality of Ambulatory Surgical Care for Skin Cancer in a Veterans Affairs Clinic and a Fee-For-Service Practice Using Clinical and Patient-Reported Measures. PLoS One. 2017; 12(1):e0171253.
  12. Mansh M, Ing L, Dimon M, Celli A, Mauro TM, Arron ST. Voriconazole exposure regulates distinct cell-cycle and terminal differentiation pathways in primary human keratinocytes. Br J Dermatol. 2017 Mar; 176(3):816-820.
  13. Dizon M, Linos E, Arron ST, Abuabara K, Ruiz de Luzuriaga AM, Jin C, Boscardin WJ, Chren MM. Comparisons of patients' satisfaction should take expectations into account. Br J Dermatol. 2017 Jan; 176(1):252-254.
  14. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
  15. Ahn R, Gupta R, Lai K, Chopra N, Arron ST, Liao W. Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics. 2016 Oct 28; 17(1):841.
  16. Faden DL, Arron ST, Heaton CM, DeRisi J, South AP, Wang SJ. Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers. J Otolaryngol Head Neck Surg. 2016 Sep 17; 45(1):47.
  17. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 Sep 01; 11(1):120.
  18. Asgari MM, Toland AE, Arron ST. IRF4 Polymorphism Is Associated with Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients: A Pigment-Independent Phenomenon. J Invest Dermatol. 2017 Jan; 137(1):251-253.
  19. Reid-Bayliss KS, Arron ST, Loeb LA, Bezrookove V, Cleaver JE. Why Cockayne syndrome patients do not get cancer despite their DNA repair deficiency. Proc Natl Acad Sci U S A. 2016 Sep 06; 113(36):10151-6.
  20. Chren MM, Arron ST. Research that Guides Clinical Decisions. J Invest Dermatol. 2016 Aug; 136(8):1535-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.